Synergistic Anticancer Effects of Silibinin and Chrysin in T47D Breast Cancer Cells

Overview

Journal Asian Pac J Cancer Prev

Specialty Oncology

Date 2017 Jun 15

PMID 28610415

Citations 20

Authors

Zahra Javan Maasomi

Younes Pilehvar Soltanahmadi

Mehdi Dadashpour

Shahriar Alipour

Somayeh Abolhasani

Nosratollah Zarghami

Affiliations

Soon will be listed here.

Abstract

Objective: Breast cancer is one of the most significant causes of female cancer death worldwide. Although several chemotherapeutics have been developed to treat this type of cancer, issues remain such as low survival rates and high reoccurrence after chemotherapy and radiotherapy. To explore a chemopreventive approach to enhancing breast cancer treatment efficacy, the antiproliferative effects of a combination of chrysin and silibinin, two herbal substances, in T47D breast cancer cells were assessed. Materials and Methods: Cytotoxicity of the agents singly and in combination was evaluated by MTT assay. Also, qRT-PCR was used to measure the expression levels of hTERT and cyclin D1 genes after 48 h treatment. Results: Cell viability assays revealed that chrysin or silibinin alone inhibited proliferation in a dose and time-dependent manner, and combining the drugs synergistically induced growth inhibition in the breast cancer cell line. The precise nature of this interaction was further analyzed by the median-effect method, where the combination indices (CI) were <1 for combination treatments, indicating synergism regarding T47D cell proliferation. qPCR results showed that the drug combination also synergistically down-regulated the mRNA levels of hTERT and cyclin D1 at all used concentrations compared with the drugs used alone after 48 h treatment (P ≤ 0.05). Conclusion: The data provide evidence that synergistic antiproliferative effects of Chrysin and Silibinin are linked to the down-regulation of cyclin D1 and hTERT genes, and suggest that their combination may have therapeutic value in treatment of breast cancer.

Citing Articles

Anticancer Activity of Ether Derivatives of Chrysin.

Sokal A, Mruczek P, Niedoba M, Dewalska A, Stocerz K, Kadela-Tomanek M Molecules. 2025; 30(4).

PMID: 40005270 PMC: 11857933. DOI: 10.3390/molecules30040960.

Medicinal plants as a potential resource for the discovery of novel structures towards cancer drug resistance treatment.

Nguyen M, Nguyen T, Le T, Le T, Chau N, Le T Heliyon. 2024; 10(20):e39229.

PMID: 39492898 PMC: 11530815. DOI: 10.1016/j.heliyon.2024.e39229.

A comprehensive evaluation of the therapeutic potential of silibinin: a ray of hope in cancer treatment.

Ray P, Islam M, Islam M, Han A, Geng P, Aziz M Front Pharmacol. 2024; 15:1349745.

PMID: 38487172 PMC: 10937417. DOI: 10.3389/fphar.2024.1349745.

Development of PEGylated PLGA Nanoparticles Co-Loaded with Bioactive Compounds: Potential Anticancer Effect on Breast Cancer Cell Lines.

Mohammadinejad S, Jafari-Gharabaghlou D, Zarghami N Asian Pac J Cancer Prev. 2022; 23(12):4063-4072.

PMID: 36579986 PMC: 9971482. DOI: 10.31557/APJCP.2022.23.12.4063.

An update of Nrf2 activators and inhibitors in cancer prevention/promotion.

Pouremamali F, Pouremamali A, Dadashpour M, Soozangar N, Jeddi F Cell Commun Signal. 2022; 20(1):100.

PMID: 35773670 PMC: 9245222. DOI: 10.1186/s12964-022-00906-3.

References

Nasiri M, Zarghami N, Koshki K, Mollazadeh M, Pourhassan Moghaddam M, Rahmati Yamchi M . Curcumin and silibinin inhibit telomerase expression in T47D human breast cancer cells. Asian Pac J Cancer Prev. 2013; 14(6):3449-53. DOI: 10.7314/apjcp.2013.14.6.3449. View

Liu L, Zhao H, Ma T, Ge F, Chen C, Zhang Y . Identification of valid reference genes for the normalization of RT-qPCR expression studies in human breast cancer cell lines treated with and without transient transfection. PLoS One. 2015; 10(1):e0117058. PMC: 4305315. DOI: 10.1371/journal.pone.0117058. View

Liu R . Potential synergy of phytochemicals in cancer prevention: mechanism of action. J Nutr. 2004; 134(12 Suppl):3479S-3485S. DOI: 10.1093/jn/134.12.3479S. View

Ting H, Deep G, Agarwal R . Molecular mechanisms of silibinin-mediated cancer chemoprevention with major emphasis on prostate cancer. AAPS J. 2013; 15(3):707-16. PMC: 3691417. DOI: 10.1208/s12248-013-9486-2. View

Eatemadi A, Daraee H, Aiyelabegan H, Negahdari B, Rajeian B, Zarghami N . Synthesis and Characterization of Chrysin-loaded PCL-PEG-PCL nanoparticle and its effect on breast cancer cell line. Biomed Pharmacother. 2016; 84:1915-1922. DOI: 10.1016/j.biopha.2016.10.095. View

Peurala E, Koivunen P, Haapasaari K, Bloigu R, Jukkola-Vuorinen A . The prognostic significance and value of cyclin D1, CDK4 and p16 in human breast cancer. Breast Cancer Res. 2013; 15(1):R5. PMC: 3672746. DOI: 10.1186/bcr3376. View

Siddiqui J, Singh A, Chagtoo M, Singh N, Godbole M, Chakravarti B . Phytochemicals for breast cancer therapy: current status and future implications. Curr Cancer Drug Targets. 2014; 15(2):116-35. DOI: 10.2174/1568009615666141229152256. View

Kapadia G, Rao G, Ramachandran C, Iida A, Suzuki N, Tokuda H . Synergistic cytotoxicity of red beetroot (Beta vulgaris L.) extract with doxorubicin in human pancreatic, breast and prostate cancer cell lines. J Complement Integr Med. 2013; 10. DOI: 10.1515/jcim-2013-0007. View

Alibakhshi A, Ranjbari J, Pilehvar-Soltanahmadi Y, Nasiri M, Mollazade M, Zarghami N . An Update on Phytochemicals in Molecular Target Therapy of Cancer: Potential Inhibitory Effect on Telomerase Activity. Curr Med Chem. 2016; 23(22):2380-93. DOI: 10.2174/0929867323666160425113705. View

10.

Mohammadinejad S, Akbarzadeh A, Rahmati-Yamchi M, Hatam S, Kachalaki S, Zohreh S . Preparation and Evaluation of Chrysin Encapsulated in PLGA- PEG Nanoparticles in the T47-D Breast Cancer Cell Line. Asian Pac J Cancer Prev. 2015; 16(9):3753-8. DOI: 10.7314/apjcp.2015.16.9.3753. View

11.

Gonzalez-Vallinas M, Gonzalez-Castejon M, Rodriguez-Casado A, Ramirez de Molina A . Dietary phytochemicals in cancer prevention and therapy: a complementary approach with promising perspectives. Nutr Rev. 2013; 71(9):585-99. DOI: 10.1111/nure.12051. View

12.

DeSantis C, Ma J, Bryan L, Jemal A . Breast cancer statistics, 2013. CA Cancer J Clin. 2013; 64(1):52-62. DOI: 10.3322/caac.21203. View

13.

Miller P, Snyder D . Phytochemicals and cancer risk: a review of the epidemiological evidence. Nutr Clin Pract. 2012; 27(5):599-612. DOI: 10.1177/0884533612456043. View

14.

Casimiro M, Arnold A, Pestell R . Kinase independent oncogenic cyclin D1. Aging (Albany NY). 2015; 7(7):455-6. PMC: 4543029. DOI: 10.18632/aging.100773. View

15.

Mocellin S, Pooley K, Nitti D . Telomerase and the search for the end of cancer. Trends Mol Med. 2012; 19(2):125-33. DOI: 10.1016/j.molmed.2012.11.006. View

16.

Mohammadian F, Pilehvar-Soltanahmadi Y, Mofarrah M, Dastani-Habashi M, Zarghami N . Down regulation of miR-18a, miR-21 and miR-221 genes in gastric cancer cell line by chrysin-loaded PLGA-PEG nanoparticles. Artif Cells Nanomed Biotechnol. 2016; 44(8):1972-1978. DOI: 10.3109/21691401.2015.1129615. View

17.

Mohan A, Narayanan S, Sethuraman S, Krishnan U . Combinations of plant polyphenols & anti-cancer molecules: a novel treatment strategy for cancer chemotherapy. Anticancer Agents Med Chem. 2012; 13(2):281-95. DOI: 10.2174/1871520611313020015. View

18.

Nejati-Koshki K, Zarghami N, Pourhassan-Moghaddam M, Rahmati-Yamchi M, Mollazade M, Nasiri M . Inhibition of leptin gene expression and secretion by silibinin: possible role of estrogen receptors. Cytotechnology. 2012; 64(6):719-26. PMC: 3488373. DOI: 10.1007/s10616-012-9452-3. View

19.

Gatouillat G, Magid A, Bertin E, El Btaouri H, Morjani H, Lavaud C . Medicarpin and millepurpan, two flavonoids isolated from Medicago sativa, induce apoptosis and overcome multidrug resistance in leukemia P388 cells. Phytomedicine. 2015; 22(13):1186-94. DOI: 10.1016/j.phymed.2015.09.005. View

20.

Kazemi-Lomedasht F, Rami A, Zarghami N . Comparison of inhibitory effect of curcumin nanoparticles and free curcumin in human telomerase reverse transcriptase gene expression in breast cancer. Adv Pharm Bull. 2013; 3(1):127-30. PMC: 3846029. DOI: 10.5681/apb.2013.021. View